Clinical trials: Covid19 Vaccination
Autoimmune or Autoinflammatory Diseases, HIV
Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People
Prospective, multicenter, non-comparative cohort study of immunocompromised people vaccinated against Covid-19 with the aim to know the humoral and cellular response to BNT162b2 vaccination against SARS-CoV-2 variants.
- Conditions
- Autoimmune or Autoinflammatory Diseases, HIV, Multiple Sclerosis, Solid Tumors or Cancers
- Trial name
- COVIVAC-ID (NCT04844489)
- Testing
- Blood samples for the study of the humoral response to SARS-CoV-2 variants and of the cellular response after vaccination against COVID-19
- Where
- France
- Volunteers
- 377 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
SARS-CoV 2, Immunization; Infection
Study to Determine the Immunization Status Among Nephrological Health Care Personnel Against SARS-CoV-2 in a Single Center Over the Course of 12 Months During the Worldwide COVID-19 Pandemic.
Infections with Corona-Viruses have shown to be a menace for patients with comorbidities such as hypertension, diabetes, cardiovascular disease or immunosuppression.
- Trial name
- CONEC (NCT04347694)
- Where
- Austria
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Health Personnel Attitude, Health Knowledge, Attitudes, Practice
Healthcare Provider Human Papillomavirus Education and Professional Skills Intervention
Healthcare providers (HCP) serving the El Paso U.S.-Mexico Border Region will be recruited to compare educational and professional skills interventions focused on the human papillomavirus (HPV).
- Trial name
- NCT05120869
- Testing
- Tailored HPV Education and Professional Skills Intervention Group, General HPV Education and Communication Skills Control Group
- Where
- 2 sites in United States
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- University of Texas, El Paso
COVID-19
Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19
The purpose of this pragmatic randomized trial is to evaluate the vaccine effectiveness of the COVID-19 vaccine, mRNA-1273, in adults aged 50-64 years without known risk factors for severe COVID-19 infection.
- Trial name
- DAN-COVID (NCT07279766)
- Testing
- mRNA-1273 (Moderna COVID-19 vaccine)
- Where
- 2 sites in Denmark
- Volunteers
- 41,060 people, healthy volunteers welcome
- Sponsor
- Tor Biering-Sørensen
COVID-19
Safety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inactivated for Prevention of COVID-19
This is a randomized, double-blinded, phase Ⅳ clinical trial of COVID-19 vaccine (Vero cell), Inactivated manufactured by Sinovac Life Sciences Co. , Ltd.
- Trial name
- NCT05165966
- Testing
- High-dosage of COVID-19 vaccine (Vero cell), Inactivated, Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated
- Where
- China
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Influenza Immunization, Healthy Volunteers
Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine
The main purpose of this Phase II study was to assess the safety and immunogenicity of a dose of Fluzone High-Dose (HD) Quadrivalent vaccine and a third dose or booster dose of Moderna coronavirus disease 19 (COVID-19) vaccine…
- Trial name
- NCT04969276
- Testing
- Quadrivalent Inactivated Influenza High Dose, COVID-19 mRNA Vaccine (nucleoside modified)
- Where
- 6 sites in United States
- Volunteers
- 306 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19
Heterologous Prime-boost Immunization with an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Priming with an Inactivated SARS-CoV-2 Vaccine
This is a randomized, open-label, parallel-controlled study to evaluate the safety and immunogenicity of heterologous prime-boost immunization with an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) after…
- Trial name
- NCT05043259
- Testing
- inactive SARS-CoV-2 vaccine (Vero cell), Low dose aerosolized Ad5-nCoV, High dose aerosolized Ad5-nCoV
- Where
- China
- Volunteers
- 423 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Covid19
Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects
VXA-CoV2-1 is a non-replicating Ad5 vector adjuvanted oral tableted vaccine being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection.
- Trial name
- NCT04563702
- Testing
- VXA-CoV2-1
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Vaxart
SARS CoV 2 Infection, COVID-19 Breakthrough
SARS-CoV-2 Specific Antibody Responses and Impact for COVID-19 Disease in Ethiopia
In this study we aim to characterize SARS CoV-2 strain specific immune response (SARS-CoV-2 Spike IgG) in health care workers and general populations at the Jimma Medical Center and the St.
- Conditions
- SARS CoV 2 Infection, COVID-19 Breakthrough, COVID-19 Recurrent
- Trial name
- CoVICIS (NCT06435403)
- Where
- 2 sites in Ethiopia
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Michael Hoelscher
Misinformation, Vaccine Hesitancy
Brief Digital Intervention to Increase COVID-19 Vaccination Among Individuals With Anxiety or Depression
The COVID-19 pandemic has led to a mis/disinformation ecosystem that promotes divergent views of vaccine efficacy, as well as the legitimacy of science and medicine.
- Conditions
- Misinformation, Vaccine Hesitancy, Anxiety, Depression
- Trial name
- NCT06119854
- Testing
- Attitudinal inoculation, Cognitive-behavioral therapy-informed intervention, Conventional public health messaging
- Where
- United States
- Volunteers
- 1,419 people
- Sponsor
- City University of New York, School of Public Health
Immune Response Post Covid 19 Vaccination
Immune Response of Haemodialysis Patients Post Covid-19 Vaccination
The purpose of this study is to assess immune response of end stage renal failure patients after Covid 19 vaccination
- Trial name
- Covid-19 (NCT04872751)
- Where
- Malaysia
- Volunteers
- 425 people
- Sponsor
- Penang Hospital, Malaysia
Covid19
SCALE-UP Utah: Community-Academic Partnership to Address COVID-19 Vaccination Rates Among Utah Community Health Centers
SCALE-UP Utah is a community-academic partnership to address COVID-19 among Utah community health centers. The long-term objective of the project is to increase the reach, acceptance, and uptake of COVID-19 vaccines among Utah's…
- Trial name
- NCT04939519
- Testing
- Text-Messaging (TM), Patient Navigation (PN)
- Where
- United States
- Volunteers
- 65,300 people, healthy volunteers welcome
- Sponsor
- University of Utah
COVID-19 Respiratory Infection
ALACOVID Study for Vaccinated Subjects
In this study, it is hypothesized that administration of 5-ALA-Phosphate + SFC in subjects vaccinated against Covid-19 could contribute in enhancing the targeted function of the immune system, which might lead to re-activation…
- Trial name
- COVID-19 (NCT05234346)
- Testing
- 150 mg 5-ALAPhosphate + SFC
- Where
- 4 sites in India
- Volunteers
- 200 people
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Rheumatic Diseases, SARS-CoV Infection
Longitudinal Follow-up of Patients With Chronic Inflammatory Rheumatisms (CIRs) Vaccinated Against COVID-19 Compared to Patients Refusing Vaccination
To date, studies on SARS-CoV2and vaccines have been mostly from the general population not exposed to immunosuppressants. The efficacy and safety of COVID-19 vaccines need to be evaluated in these populations.
- Conditions
- Rheumatic Diseases, SARS-CoV Infection, COVID-19
- Trial name
- COVID-RIC3 (NCT04832022)
- Testing
- Biological samples
- Where
- 13 sites in France
- Volunteers
- 397 people
- Sponsor
- University Hospital, Montpellier
Vaccine Hesitancy
Investigation on the Hesitancy of COVID-19 Vaccination Among Liver Transplant Recipients in China
On WeChat platform, through a point-to-point connection, and carry on the questionnaire survey to collect information of liver transplant recipients followed-up by the department of Liver Surgery, Renji Hospital Shanghai Jiao…
- Trial name
- NCT05532592
- Testing
- Perceptions and attitudes towards COVID-19 and COVID-19 vaccine
- Where
- China
- Volunteers
- 449 people
- Sponsor
- RenJi Hospital
Lung Cancer, Covid19
Anti-SARS-COV2 Vaccination Study in Lung Cancer Patients
Observational and multicenter retrospective study of data collection in hospital centers throughout the Spanish geography. This study aims to be nationwide in order to study general common variables of the patients, as well as…
- Trial name
- VAC-CaP (NCT05009030)
- Testing
- COVID-19 vaccine
- Where
- 51 sites in Spain
- Volunteers
- 794 people
- Sponsor
- Fundación GECP
SARS-CoV2 Infection, Coronavirus Infection
Fourth Dose of mRNA COVID-19 Vaccine in Residents of LTCFs
This study is a multi-centre, blinded, randomized controlled trial. LTCF residents ≥ 65 years who have received three doses of mRNA vaccine will be randomized to vaccination with a fourth dose of Pfizer-BioNtech mRNA- COVID-19…
- Trial name
- NCT04978038
- Testing
- mRNA- COVID-19, Prevnar13
- Where
- Canada
- Volunteers
- 414 people, healthy volunteers welcome
- Sponsor
- Mark Loeb
COVID-19, Sars-CoV-2 Infection
Phase 3 Booster Vaccination Against COVID-19
The inactivated Booster Phase 3 study aims to determine the efficacy, safety, and immunogenicity of inactivated COVID-19 vaccines in subjects with a minimum of 90 days and a maximum of 270 days after the second dose of CoronaVac…
- Trial name
- NCT05077176
- Testing
- CoronaVac, Turkovac
- Where
- 41 sites in Turkey (Türkiye)
- Volunteers
- 4,340 people, healthy volunteers welcome
- Sponsor
- Health Institutes of Turkey
Rheumatic Diseases
COVID-19 Vaccination in Patients With Rheumatic Diseases
The Argentine Society of Rheumatology (SAR) set out to develop a national register of patients with rheumatic diseases who have received a SARS-CoV-2 vaccine in order to assess their efficacy and safety in this population.
- Trial name
- SAR-CoVAC (NCT04845997)
- Testing
- COVID-19 Vaccine
- Where
- 2 sites in Argentina
- Volunteers
- 3,000 people
- Sponsor
- Sociedad Argentina de Reumatologia
COVID-19
A Clinical Trial on Booster Immunization of Two COVID-19 Vaccines Constructed From Different Technical Routes
This is an open-label, randomized, parallel-controlled clinical trial conducted in people aged 18 years and older to evaluate the immunogenicity and safety of two SARS-CoV-2 bivalent vaccines constructed by adenovirus type…
- Trial name
- NCT05886790
- Testing
- Prototype and Omicron BA.4/5 Bivalent Recombinant COVID-19 Vaccine(Adenovirus Type 5 Vector) For Inhalation, Bivalent COVID-19 mRNA Vaccine, Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) For Inhalation
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Zhongnan Hospital